Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2005

View Archived Issues

FR-255031 prevents progression of joint destruction in arthritic rats

Nonimmunosuppressive immunophilin FK-1706 potentiates neurite outgrowth in vitro

Novel therapeutic strategy for heart failure effective in dogs

New data on the pharmacokinetics of roflumilast in pediatric patients

Clinical evidence supports the use of TroVax in metastatic colorectal cancer

Clinical evaluation of prasugrel as inhibitor of platelet aggregation

Flamel Technologies terminates Genvir license agreement with Biovail

SPA agreement for pivotal study of INO-1001

New phase I/II study evaluates Amplimexon plus gemcitabine

HEALOS(R)-MP52 advantageous in treating long bone defects

Istradefylline maintains efficacy in Parkinson's disease over one year

Coenzyme Q10 use remains limited in Parkinson's disease outpatients

In vivo efficacy of combined warfarin/probucol therapy for steroid-induced osteonecrosis

Chinese clinical program progresses for Calypte's HIV-1/2 tests

Senexis and BioFocus to develop novel small-molecule drugs for Alzheimer's

Pivotal trial brought forward for phenoxodiol for chemoresistant ovarian cancer

Remodulin receives the first European approval in France

Enrollment reaches half way in phase III HIV prevention study of Savvy

Promising findings for VNS Therapy in bulimia nervosa

New Melanotan trials cleared to begin in Australia and Finland

Tsumura discontinues development of TJN-598

Org-24461 reverses negative symptoms of schizophrenia in preclinical models / News in Context

Seletracetam reduces levodopa-induced dyskinesia in marmosets

Induction of HSP70 produces neuroprotective effects

Indoleamine 2,3-dioxygenase inhibitors improve chemotherapy / News in Context

Novel cathepsin S inhibitors disclosed by IRM

HIV reverse transcriptase inhibitors discovered at the University of Illinois

Galderma discloses new PPARgamma receptor agonists

HER (erbB) family kinase inhibitors for the treatment of cancer reported by GSK

Merck claims new KSP inhibitors and their use in treating cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...